Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts enormous sales potential for novel cancer therapies entering the market over the next 15 years. The identification of multiple novel targets resulting in opportunities to launch numerous new and premium-priced targeted agents into the market and the increased use of combinations of well-tolerated targeted therapies will contribute to the market's growth.

According to a new Pharmacor report entitled Early Stage Anti-Cancer Drugs, five new classes of cancer drugs will jointly account for more than $20 billion in sales in 2021. The classes include inhibitors of apoptosis (lead companies in this area are Genentech, Amgen, Human Genome Sciences, and GlaxoSmithKline), inhibitors of down-stream signaling (lead companies in this area include Pfizer, Array, and Novartis), inhibitors of DNA repair (lead company in this area is AstraZeneca), inhibitors of cell cycle kinases (lead companies in this area include AstraZeneca, Merck, Cyclacel, and Vertex), and inhibitors of heat shock proteins (lead companies in this area are Kosan and Biogen Idec).

The launch of targeted therapies in cancer imposes a large economic burden on society because of their premium prices and increasing treatment durations.

"To maximize the cost-to-benefit ratio, clinicians will want to identify up front potential responders over patients unlikely to benefit from treatment," said Joanne Graham, Ph.D., therapeutic area director at Decision Resources. "And, in guarded markets, the use of premium-priced drugs will be constrained despite data to support clinical benefit."

About Pharmacor

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Erbitux Will Reach $250 Million in Sales in 2015, a Five-Fold Increase in the Value of the Entire 2005 Head and Neck Cancer Drug Market

View Now